Search VCNX
Vaccinex, Inc.
OTC Markets OTCPK · CIK 1205922
Last close1.01
Daily change-0.02 (-1.94%)
10 Years gain-99.96%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
VCNX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
36.1Momentum
0.0Acceleration
0.0Confidence
69.0Annual Revenue8
Quarterly Revenue20
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality3.0 / 25
Capital Efficiency15.1 / 20
Balance Sheet11.1 / 15
Shareholder Economics5.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Negative FCF · HIGHLatest free cash flow is negative.
Operating margin compression · MEDIUMOperating margin compressed by 1581.721 percentage points.
Heavy share dilution · HIGHDiluted share count increased 529.1793%.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM-37.42%OK
Revenue CAGR 3Y-12.59%OK
Gross Marginn/aMISSING
Operating Margin-5,241.24%OK
FCF Margin-5,157.99%OK
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO0.14xOK
Diluted Share Growth 1Y529.18%OK
SBC / Revenue100%OK
SBC / FCF-1.94%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 FY Dec 31, 2024 | $601,000.00 | n/a | -$18.74M | -$16.19M | -$16.21M | n/a | -3,117.3% | -2,696.84% | n/a | 2.1M |
| 2024 FY Dec 31, 2023 | $570,000.00 | n/a | -$22.89M | -$21.38M | -$21.45M | n/a | -4,014.91% | -3,762.46% | n/a | 463,653 |
| 2023 FY Dec 31, 2022 | $275,000.00 | n/a | -$19.91M | -$19.07M | -$19.17M | n/a | -7,238.55% | -6,972% | n/a | 202,082 |
| 2022 FY Dec 31, 2021 | $900,000.00 | n/a | -$22.49M | -$25.30M | -$25.33M | n/a | -2,498.89% | -2,814.44% | n/a | 28.85M |
| 2021 FY Dec 31, 2020 | $625,000.00 | $623,000.00 | -$28.33M | -$28.65M | -$28.94M | 99.68% | -4,532.96% | -4,629.92% | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $388,000.00 | sum latest 4 fiscal quarters Revenue | OK | 0000950170-25-054318, 0000950170-24-060603 |
| Revenue Growth TTM | -37.42% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000950170-25-054318, 0000950170-24-060603 |
| Revenue CAGR 3Y | -12.59% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000950170-25-054318 |
| Revenue CAGR 5Y | 2.82% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000950170-25-054318 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000950170-25-054318, 0000950170-24-060603 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | 0000950170-25-054318, 0000950170-24-060603 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -5,241.24% | Operating Income / Revenue | OK | 0000950170-25-054318, 0000950170-24-060603 |
| FCF Margin | -5,157.99% | (CFO - CapEx) / Revenue | OK | 0000950170-25-054318, 0000950170-24-060603 |
| Net Debt / CFO | 0.14x | Net Debt / CFO | OK | 0000950170-24-127139, 0000950170-25-054318 |
| Current Ratio | 0.77x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 66.05x | (Cash + Short-term Investments) / Total Debt | OK | 0000950170-24-127139 |
| SBC / Revenue | 100% | SBC / Revenue | OK | 0000950170-25-054318, 0000950170-24-060603 |
| Revenue per Diluted Share | $0.19 | Revenue / Diluted Shares | OK | 0000950170-25-054318, 0000950170-24-060603 |